Health News Releases

  • Today December 20
December 09, 2019 14:31
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (
December 06, 2019 11:06
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement highlighting a troubling voting scheme
December 05, 2019 12:22
Macrogen Research Outcome from ‘GenomeAsia 100K’ Covered in Nature
The precision medicine and biotechnology company Macrogen (Chairman Jung-Sun Seo, www.macrogen.com) (KOSDAQ: 038290) announced on Dec 5 that the result of its Asian genome analysis, which has been per
December 03, 2019 11:13
Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019
Octapharma has announced that the final results of the NuProtect study will be presented by Dr Ri Liesner (Great Ormond Street Hospital for Children, London, UK) as an oral presentation at the 61st An
December 03, 2019 10:24
OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements
OncoSec Medical Incorporated (NASDAQ: ONCS), (the “Company” or “OncoSec”) a company developing late-stage intratumoral cancer immunotherapies, today issued the following letter to shareholders. The fu
November 27, 2019 11:14
GN CORPORATION: Vision Restored with Corneal Cell Transplant Using a Nano Sheet Technique; Japanese Firm Granted Patent in India
A novel cell transplantation method to treat corneal endothelial diseases such as bullous keratopathy using a nano-composite gel sheet developed by Japanese scientists was granted Indian patent to GN
November 26, 2019 17:08
Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502 / NYSE:TAK) (“Takeda”) today announced that updated results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TID
November 26, 2019 11:48
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lym
November 26, 2019 10:09
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patien
November 26, 2019 09:11
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in
November 25, 2019 13:44
Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients
Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient S
November 22, 2019 11:21
PanTheryx Announces Exclusive Multimillion Dollar Agreement between APS BioGroup and VitaDairy in Pediatric and Maternal Immunonutrition
PanTheryx, a biotechnology company committed to realizing the potential of bovine colostrum-based therapies, today announced a multimillion dollar agreement between its wholly-owned subsidiary APS Bio
November 18, 2019 14:00
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding
November 18, 2019 10:41
Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world study on effectiveness shows that empagliflozin was associated with a decreas
November 15, 2019 11:37
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches in the Next Five Years at 2019 R&D Day
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first, patient-centric strat
November 14, 2019 06:00
College of American Pathologists and Seoul National University Host Advanced Education for Doctors and Laboratory Scientists
In an effort to foster laboratory quality and further advance the evolving field of clinical microbiology, the College of American Pathologists (CAP), in partnership with Seoul National University Col
November 13, 2019 10:38
Cook Medical’s Leadership Updates in Asia-pacific Reinforce Focus on Growth and Physician Relationships
Cook Medical announced today that Jean-Marc Creissel has been named vice president and director of Asia-Pacific. In his new role, Creissel will lead the Asia-Pacific teams to transform Cook Medical
November 13, 2019 10:00
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whet
November 12, 2019 17:56
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the c
November 12, 2019 10:45
Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American Society of Hematology (ASH) Annual Meetin
November 11, 2019 11:09
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance R&D Across Two Separate Programs for Oncology
Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclica’s proprietary AI-integ
November 11, 2019 09:55
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in p
November 08, 2019 16:35
Phase 3 Trial of NINLARO™ (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The tri
November 08, 2019 14:38
FIND Collaborates with SpeeDx and QuantuMDx
SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery
November 07, 2019 19:36
Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®
Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) tech
25 per page50 per page75 per page100 per page